Dear Dr. [Last name],
When treating deep vein thrombosis (DVT) and pulmonary embolism (PE), many considerations may impact your treatment choice. SAVAYSA, the latest novel oral anticoagulant (NOAC), offers the convenience of once-daily dosing1 and monthly prescription savings. The SAVAYSA Support+™ program, including the SAVAYSA Savings Card offers eligible patients to pay no more than $4 per month for their SAVAYSA prescription. Connect your patients with support and potential savings with SAVAYSA Support+™
|
|
|
|
SAVAYSA may fit into your patient's life with once-daily dosing and SAVAYSA Support+™
|
|
|
|
Connect your patients with support and potential savings. SAVAYSA Support+™ includes:
|
| • |
Helpful tips and information about NVAF |
| • |
Helpful tips and information about treatment with SAVAYSA (edoxaban) |
| • |
The SAVAYSA Savings Card, allowing eligible patients to save on their SAVAYSA prescription†
|
|
|
†Restrictions apply; see Eligibility Criteria and Terms & Conditions below. Card is valid for $4 for a 30-day prescription and $12 for a 90-day prescription. Patient responsible for applicable taxes, if any. Not valid if enrolled in state or federally funded prescription benefit program (eg, Medicare Part D/Medicaid) or if prohibited by law. Daiichi Sankyo, Inc., reserves the right to rescind, revoke, or amend this program, at any time, without notice.
|
|
Reimbursement support for your patients to help fill their SAVAYSA prescription
|
|
Let CoverMyMeds® help provide reimbursement support for your patients.
|
|
|
|
Questions? Call or chat for help. Phone: 866-452-5017 | Live chat: covermymeds.com Mon–Fri: 8 AM–11 PM ET, Sat: 8 AM–3 PM ET
|
|
Download SAVAYSA Support+™ fact sheets for your patients below, or encourage your patients to visit savaysa.com.
|
|
|
|
The once-daily NOAC superior to warfarin with less clinically relevant bleeding in DVT/PE patients initiated with 5 to 10 days of a parenteral anticoagulant1*
|
| • |
19% relative risk reduction (RRR), 1.8% absolute risk reduction (ARR): 8.5% with SAVAYSA vs 10.3% with warfarin (HR [95% CI]: 0.81 [0.71-0.94]); P=0.004 |
|
|
Noninferior vs well-managed warfarin in reducing the rate of recurrent DVT/PE‡§
|
| • |
3.2% with SAVAYSA vs 3.5% with warfarin (HR [95% CI]: 0.89 [0.70-1.13]) |
|
|
*Clinically relevant bleeding (the study primary safety endpoint) was defined as a composite of major and clinically relevant non-major (CRNM) bleeding. A Major Bleeding event was defined as clinically overt bleeding that met one of the following criteria: associated with a fall in hemoglobin level of 2.0 g/dL or more, or leading to transfusion of 2 or more units of packed red cells or whole blood; occurring in a critical site or organ: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; contributing to death. CRNM bleeding was defined as overt bleeding not meeting the criteria for a Major Bleeding event but that was associated with a medical intervention, an unscheduled contact (visit or telephone call) with a physician, temporary cessation of study treatment, or associated with discomfort for the subject such as pain, or impairment of activities of daily life.
|
|
‡The primary efficacy endpoint of the study was symptomatic VTE, defined as the composite of recurrent DVT, new nonfatal symptomatic PE, and fatal PE during the 12-month study period.
|
|
§Median time in therapeutic range (INR target 2.0 to 3.0): 66%.
|
|
|
|
To learn more about how SAVAYSA compares to warfarin and to sign up to receive samples and patient resources, visit savaysahcp.com.
|
Indication
SAVAYSA® (edoxaban) is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant.
Important Safety Information for SAVAYSA |
| Boxed Warnings |
| • |
PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK
OF ISCHEMIC EVENTS |
|
| Premature discontinuation of any oral anticoagulant in the absence of adequate alternative anticoagulation increases the risk of ischemic events. If SAVAYSA is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant as described in the transition guidance in the Prescribing Information. |
| • |
SPINAL/EPIDURAL HEMATOMA |
|
| – |
Epidural or spinal hematomas may occur in patients treated with SAVAYSA who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures |
| – |
Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters; concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants; a history of traumatic or repeated epidural or spinal punctures; a history of spinal deformity or spinal surgery |
| – |
Optimal timing between the administration of SAVAYSA and neuraxial procedures is not known |
|
| Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary. Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated. |
|
| CONTRAINDICATIONS |
| SAVAYSA is contraindicated in patients with active pathological bleeding. |
| WARNINGS AND PRECAUTIONS |
| Bleeding Risk |
|
SAVAYSA increases the risk of bleeding and can cause serious and potentially fatal bleeding. Promptly evaluate any signs or symptoms of blood loss. Discontinue SAVAYSA in patients with active pathological bleeding. Concomitant use of drugs affecting hemostasis may increase the risk of bleeding. These include aspirin and other antiplatelet agents, other antithrombotic agents, fibrinolytic therapy, and chronic use of nonsteroidal antiinflammatory drugs. There is no established way to reverse the anticoagulant effects of SAVAYSA, which can be expected to persist for approximately 24 hours after the last dose. The anticoagulant effect of SAVAYSA cannot be reliably monitored with standard laboratory testing. A specific reversal agent for edoxaban is not available. Hemodialysis does not significantly contribute to edoxaban clearance. Protamine sulfate, vitamin K, and tranexamic acid are not expected to reverse its anticoagulant activity. |
| Mechanical Heart Valves or Moderate to Severe Mitral Stenosis |
|
The safety and efficacy of SAVAYSA has not been studied in patients with mechanical heart valves or moderate to severe mitral stenosis. SAVAYSA is not recommended in these patients. |
| ADVERSE REACTIONS |
| • |
The most common adverse reactions (≥1%) are bleeding, rash, abnormal liver function tests and anemia |
|
| DISCONTINUATION FOR SURGERY AND OTHER INTERVENTIONS |
| Discontinue SAVAYSA at least 24 hours before invasive or surgical procedures because of the risk of bleeding. SAVAYSA can be restarted after the surgical or other procedure as soon as adequate hemostasis has been established. |
| DRUG INTERACTIONS |
| • |
Anticoagulants, Antiplatelets, and Thrombolytics: Coadministration of anticoagulants, antiplatelet drugs, and thrombolytics may increase the risk of bleeding |
| • |
P-gp Inducers: Avoid concomitant use of SAVAYSA with rifampin |
| • |
P-gp Inhibitors: Coadministration of certain P-gp inhibitor medications requires a dose reduction of SAVAYSA to 30 mg once daily |
|
| SPECIAL POPULATIONS |
| • |
Nursing mothers: Discontinue drug or discontinue nursing |
| • |
Impaired renal function (CrCl 15 to 50 mL/min): Reduce SAVAYSA dose to 30 mg once daily |
| • |
Moderate or severe hepatic impairment: Not recommended |
| • |
Pregnancy Category C |
|
| Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide. |
|
SAVAYSA® (edoxaban) Savings Card:
|
| Eligibility Criteria and Terms & Conditions |
Eligibility Criteria: Residents of US or Puerto Rico, 18 years of age or older, with valid prescription for SAVAYSA. Not valid if enrolled in state or federally funded prescription benefit program, including but not limited to Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DoD) or TriCare programs, or if prohibited by law. Patients who move from commercial to state or federally funded prescription insurance will no longer be eligible.
Terms & Conditions: For patients with commercial insurance, or patients without insurance, this savings card is applied after the following out-of-pocket expenses are met: $4 for a 30-day prescription or $12 for a 90-day prescription. This card is not insurance and does not cover deductibles. The maximum benefit is $350 per 30-day prescription or $1,050 per 90-day prescription. For patients with commercial insurance, card activation must occur by 12/31/16 and program expiration is 12/31/17. For patients without insurance, card activation must occur by 12/31/15 and program expiration is 12/31/16. This offer is not conditioned on any past, present, or future purchases, including refills. Patients, pharmacists, and prescribers cannot seek reimbursement from health insurance or any third party for any part of the benefit received by patients through this offer. Patient acceptance (use) of this offer constitutes an acknowledgement that it is not prohibited by the patient's insurance, and that patient will report the value received if required by the insurance provider. This offer is non-transferable and no substitutions are permissible. Offer cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription. Reproductions of the card are void. If your pharmacy does not accept the SAVAYSA Savings Card, visit www.patientrebateonline.com for instructions on how to obtain the savings benefit or call the number below. This is not insurance.
By using this card, you certify you meet the Eligibility Criteria and Terms & Conditions.
Pharmacist & Patient Questions: Call 1-844-728-2972 (8 AM–8 PM ET, M–F). Pharmacist Conditions: By using this card, you certify that the Eligibility Criteria are met. Submit transaction to McKesson Corp, using BIN #610524. If primary coverage exists, input card information as secondary coverage and transmit using COB segment of NCPDP transaction. Applicable discounts will be displayed in the transaction response. Acceptance of this card and your submission of claims for the SAVAYSA Savings Card program are subject to SAVAYSA Savings Card program Terms & Conditions posted at www.mckesson.com/mprstnc.
Daiichi Sankyo, Inc., reserves the right to rescind, revoke, or amend this program, at any time, without notice. SAVAYSA and the SAVAYSA logo are registered trademarks of Daiichi Sankyo, Inc.
|
| Reference: |
| 1. SAVAYSA® [package insert], Parsippany, NJ: Daiichi Sankyo, Inc; 2015. |
